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OBJECTIVE— People with type 2 diabetes are at increased risk of cognitive impairment but
the mechanism is uncertain. Elevated glucocorticoid levels in rodents and humans are associated
with cognitive impairment. We aimed to determine whether fasting cortisol levels are associated
with cognitive ability and estimated lifetime cognitive change in an elderly population with type
2 diabetes.
RESEARCH DESIGN AND METHODS— This was a cross-sectional study of 1,066
men and women aged 60–75 years with type 2 diabetes, living in Lothian, Scotland (the
Edinburgh Type 2 Diabetes Study). Cognitive abilities in memory, nonverbal reasoning, infor-
mation processing speed, executive function, and mental flexibility were tested, and a general
cognitive ability factor, g, was derived. Prior intelligence was estimated from vocabulary testing,
and adjustment for scores on this test was used to estimate lifetime cognitive change. Relation-
ships between fasting morning plasma cortisol levels and cognitive ability and estimated cogni-
tive change were tested. Models were adjusted for potential confounding and/or mediating
variables including metabolic and cardiovascular variables.
RESULTS— In age-adjusted analyses, higher fasting cortisol levels were not associated with
current g or with performance in individual cognitive domains. However, higher fasting cortisol
levels were associated with greater estimated cognitive decline in g and in tests of working
memory and processing speed, independent of mood, education, metabolic variables, and car-
diovascular disease (P  0.05).
CONCLUSIONS— High morning cortisol levels in elderly people with type 2 diabetes are
associated with estimated age-related cognitive change. Strategies targeted at lowering cortisol
action may be useful in ameliorating cognitive decline in individuals with type 2 diabetes.
Diabetes Care 33:714–720, 2010
T ype 2 diabetes is associated withcognitive impairments, includingdeficits in processing speed, execu-
tive function and declarative memory,
and with structural changes in the brain
including reductions in hippocampal and
amygdalar volumes, which are key areas
influencing learning and long-term mem-
ory (1,2). Hyperglycemia, cerebral micro-
vascular disease, and recurrent severe
hypoglycemic episodes have all been im-
plicated as potential causative factors of
cognitive decline (3) but are unlikely to
explain the entire effect of diabetes on
cognition.
Increasing evidence supports a link
between elevated plasma glucocorticoids
and cognitive dysfunction. Exogenous
glucocorticoid administration and ele-
vated endogenous glucocorticoids (as
occurs in Cushing’s syndrome) are asso-
ciated with cognitive impairment in ani-
mals and humans. More subtle alterations
in hypothalamic-pituitary-adrenal (HPA)
axis function have also been linked with
cognitive function, with higher plasma
cortisol levels at 0900 h being associated
with poorer age-related cognitive ability
in a small group of elderly, healthy male
volunteers (4). Conversely, manipula-
tions that reduce plasma glucocorticoid
concentrations or their effects on target
tissues can attenuate cognitive decline
with ageing in rodents (5,6). Elevated glu-
cocorticoid levels have widespread effects
within the central nervous system, in-
cluding deleterious effects on the struc-
ture and function of the hippocampus, a
key locus for cognitive function, which
also highly expresses glucocorticoid re-
ceptors (7,8).
Several studies have demonstrated
that people with type 2 diabetes have ac-
tivation of the HPA axis, manifested by
elevated basal plasma cortisol levels
(9,10), higher late-night salivary cortisol
levels (11), elevated ACTH levels (12), in-
creased cortisol levels following overnight
dexamethasone suppression (13,14), and
impaired habituation of cortisol levels to
repeated stress (15). These findings are
consistent with a central dysregulation of
the HPA axis in type 2 diabetes. The ele-
vated plasma cortisol levels are associated
with metabolic abnormalities in diabetes
(16) and with complications of diabetes,
including retinopathy, neuropathy, and
nephropathy (17).
Investigators have started to explore
whether altered HPA axis activity contrib-
utes to cognitive impairment in diabetes.
Impaired central negative feedback con-
trol of the HPA axis, as indicated by
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higher cortisol levels after 1.5 mg dexa-
methasone administration, was related to
declarative memory impairments, possi-
bly reflecting hippocampal dysfunction,
in 30 individuals with type 2 diabetes
compared with age-, sex-, and education-
matched control subjects (18). However,
the association between cortisol and cog-
nitive function disappeared after adjust-
ment for glycemic control (A1C). The
same investigators reported similarly im-
paired HPA axis feedback control in asso-
ciation with verbal declarative memory
deficits in 41 subjects with type 2 diabetes
(1). In the latter study, the subjects with
type 2 diabetes also had reduced hip-
pocampal and prefrontal volumes, but
there were no significant associations be-
tween the cortisol measurements and
magnetic resonance image findings (1).
Despite these findings from animal
and human studies, information from
large-scale epidemiological studies of rep-
resentative populations is lacking, which
could confirm or refute an association be-
tween circulating plasma cortisol levels
and age-related cognitive impairment.
We therefore examined the relationship
between fasting cortisol and both late-life
cognitive ability and estimated lifetime
cognitive change in a large, representative
study population of people with type 2
diabetes (the Edinburgh Type 2 Diabetes
Study [ET2DS]). The ET2DS has the ad-
vantage over many previous epidemiolog-
ical studies of having detailed cognitive
testing in a range of cognitive domains
and very extensive phenotyping for po-
tential confounding or mediating factors.
RESEARCH DESIGN AND
METHODS— This report on the study
cohort is based upon the cross-sectional
phase of the ET2DS, an epidemiological
study investigating mechanisms and risk
factors for diabetes-related cognitive de-
cline and for the development and pro-
gression of micro- and macrovascular
disease in diabetes (19). Participants in
the ET2DS, aged 60–75 years, were re-
cruited at random from a comprehensive
database of all subjects with established
type 2 diabetes, living in the Lothian area
of central Scotland between August 2006
and August 2007. Recruitment and exam-
ination of the study cohort has been de-
scribed in detail previously (19). Ethical
approval was obtained from the local re-
search ethics committee, and all subjects
gave written, informed consent. Subjects
taking glucocorticoid therapy by any
route within the last 3 months (n 147)
were also excluded from the current anal-
ysis, leaving a sample size of 919.
Clinical protocol
Briefly, subjects attended a local research
clinic after an overnight fast. A fasting ve-
nous blood sample was taken between
0800 h and 0830 h, for measurement of
cortisol and other biochemical parame-
ters. Subjects completed questionnaires
describing baseline demographics and
underwent detailed physical examination
and cognitive testing.
Subjects completed a self-adminis-
tered questionnaire, including validated
questions on education (highest level at-
tained); a medical diagnosis of myocardial
infarction, stroke, or angina; duration of
diabetes; smoking; frequency of alcohol
consumption over the last year; and the
World Health Organization chest pain
questionnaire. Height, weight, brachial
blood pressure, and posterior tibial and
dorsalis pedis systolic pressures (for cal-
culation of the ankle-brachial index
[ABI]) were measured and an electrocar-
diogram was (ECG) recorded. Data were
collected from the information and statis-
tics division of the National Health Ser-
vice Scotland on all medical and surgical
discharges from Scottish hospitals since
1981 (SMR01 scheme). Any ICD-10 or
ICD-9 codes for cardiovascular or cere-
brovascular disease were extracted and
used together with self-reported vascular
disease and findings from the chest pain
questionnaire and ECG (in addition to a
review of clinical notes where required) to
define myocardial infarction, angina, and
stroke, according to predefined criteria.
Cognitive assessment
Cognitive ability was assessed on the
same morning as the blood sampling and
physical examination, after subjects had
eaten a snack and blood glucose was con-
firmed as 4 mmol/l, using a battery of
psychometric tests, providing a compre-
hensive and validated assessment of cog-
nitive function and mood state (19).
These included tests of nonverbal mem-
ory and immediate and delayed verbal
memory (faces and family pictures subtest
[FACES]), logical memory (LM) (from the
Wechsler Memory Scale III U.K.), work-
ing memory, nonverbal reasoning, pro-
cessing speed (letter-number sequencing
[LNS]), matrix reasoning (MR), digit sym-
bol test (DST) (from the WAIS III U.K.),
executive function (verbal fluency test
[VFT]), and mental flexibility (trail-
making test, part B [TMT]). A test of vo-
cabulary (typically used to assess
“crystallized” intelligence) was also in-
cluded, using the combined Junior and
Senior Mill Hill Vocabulary Scale (MHVS)
synonyms (19). As results on vocabulary
tests such as the MHVS vary little with
aging, they are used to approximate peak
prior cognitive ability. Subjects were also
assessed using the Hospital Anxiety and
Depression Scale (HADS), since mood
can affect cognitive test results.
Laboratory analysis
Plasma cortisol levels were measured by
radioimmunoassay (MP Biomedicals,
Cambridge, U.K.) with intra-assay coeffi-
cient of variation (CV) 5.1–7.0% and in-
terassay CV 6.0–7.9%.
Statistical analysis
Data were analyzed using SPSS version
15.0. As the distribution of TMT scores
was skewed, we used natural log to trans-
form TMT scores (lnTMT). Scores from
the seven cognitive tests were used to test
for the presence of a general cognitive abil-
ity factor, g, via a principal-components
analysis. Scree slope analysis indicated
that there was only a single principal com-
ponent, which accounted for 44.0% of
the total test variance. Each individual test
loaded strongly on the first unrotated
principal component (g; range 0.454 –
0.794); only the loading for the TMT was
negative (0.794) due to a high score on
this test reflecting lower cognitive ability.
To examine associations between cor-
tisol levels and current cognitive ability,
linear regression was used to assess the
association between cortisol and unad-
justed cognitive test scores and then age-
and sex-adjusted cognitive test scores. To
examine associations between cortisol
levels and estimated lifetime cognitive
change, linear regression was used with
additional adjustment for MHVS. A fur-
ther model also included adjustment for
additional covariates to control for mood
(HADS score), duration of diabetes and
glycemic control (A1C), cardiovascular
risk factors (total cholesterol, BMI, hyper-
tension, smoking, and alcohol intake),
cardiovascular disease (myocardial in-
farction, angina, stroke, ABI), and level of
education. Finally, we tested all the inter-
action terms between cortisol and all the
variables included in the regression anal-
ysis. Significant interaction terms were
entered into a further regression model.
Reynolds and Associates
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RESULTS
Subject characteristics and potential
confounding factors
Characteristics of the study population
are shown in Table 1. Characteristics of
the 919 subjects who were recruited into
the ET2DS were similar to those of non-
responders in terms of age, multiple de-
privation category, duration of diabetes,
A1C levels, the proportion using insulin,
total cholesterol, and systolic blood pres-
sure (data not shown). Table 2 shows the
correlations between cortisol and cogni-
tive and metabolic variables. Cortisol lev-
els were similar in men and women.
Cortisol levels increased slightly with age
but did not differ according to smoking or
alcohol consumption, marital status, or
education. All tests of cognitive function
were poorer with increasing age and those
with higher HADS depression scores.
Cortisol and cognitive ability
In univariate analyses, cortisol was not as-
sociated with current general cognitive
ability (g) or with individual tests of cog-
nitive function (Table 3). Trends for an
association of higher cortisol levels with
poorer working memory and processing
speed (assessed by LNS and DST) were
absent after adjustment for age and sex
(Table 3, model 1). Cortisol was not asso-
ciated with peak prior cognitive ability
measured by MHVS.
After adjustment for MHVS to esti-
mate cognitive change from an individu-
al’s estimated prior function and age and
sex, higher cortisol levels were associated
with poorer working memory (LNS) and
processing speed (DST) (P 0.05) (Table
3, model 2). These associations persisted
(P 0.05) after inclusion of other poten-
tial confounding factors in the model (Ta-
ble 3, model 3).
Finally, we tested for interaction
terms between cortisol and all the vari-
ables included in the regression analysis
(Table 3, model 4). There were no signifi-
cant interaction terms for any of the cog-
nitive domains other than for LNS and g.
In the regression analysis for LNS, two
interaction terms entered the equation,
namely cortisol by ABI and cortisol by al-
cohol. Inclusion of these interaction
terms modestly altered , but the model
remained significant. In the regression
analysis for g, there was also an interac-
tion between cortisol and ABI. Inclusion
of this interaction term resulted in the fi-
nal model achieving statistical signifi-
cance. Results of this model are illustrated
Table 1—Characteristics of study participants in ET2DS
All subjects
n 919
Sociodemographic and lifestyle variables
Age at assessment (years) 67.9 (4.2)
Marital status
Married 649 (70.8)
Living with long-term partner 49 (5.3)
Single 131 (14.3)
Widowed 88 (9.6)
Education
University/college 148 (16.1)
Other professional qualification 265 (28.8)
Secondary school 500 (54.4)
Primary school 6 (0.7)
Current smoking 120 (13.1)
Alcohol consumption (frequency)
Never 187 (20.5)
One to four times/month 402 (44.0)
Two to five times/week 229 (25.1)
Six or more times/week 96 (10.5)
Cognitive assessment
Mini-Mental State Examination 28.3 (1.9)
MHVS 31.0 (5.2)
Faces and family pictures subtest 65.9 (7.9)
Logical memory 25.2 (8.2)
LNS 9.7 (2.7)
Matrix reasoning 13.0 (5.3)
DST 49.5 (14.9)
Verbal fluency test 36.9 (12.8)
lnTMT 4.68 (0.4)
General cognitive ability factor (g) 0.01 (0.99)
Anxiety and depressive symptoms
HADS anxiety score 5.6 (3.9)
HADS depression score 3.8  2.8
Plasma cortisol levels (nmol/l) 733 (192)
Diabetes and metabolic variables
Duration of diabetes (years) 9.1 (6.5)
Systolic blood pressure (mmHg) 133.2 (16.3)
Diastolic blood pressure (mmHg) 69.1 (9.1)
Total cholesterol (mmol/l) 4.3 (0.9)
A1C (%) 7.4 (1.1)
BMI (kg/m2) 31.3 (5.6)
Ischemic heart disease (angina or myocardial infarction) 278 (30.3)
Myocardial infarction 126 (13.7)
Angina 252 (27.4)
ABI* 0.98 (0.21)
Cerebrovascular disease (transient ischemic attack or stroke) 81 (8.8)
Treatments
Treatment of diabetes
Diet alone 171 (18.6)
Hypoglycemic oral agents 590 (64.2)
Insulin with or without hypoglycemic oral agents 158 (17.2)
Lipid-lowering drugs 777 (84.5)
Antihypertensive treatment 725 (78.9)
Antidepressant(s) 108 (11.8)
Data are means SD or n (%). *ABI, lowest ankle systolic pressure divided by higher of two brachial systolic
pressures, a measure of subclinical atherosclerosis.
Cortisol and cognition in type 2 diabetes
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in Fig. 1 and in online appendix Table 1
(available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1796/DC1).
CONCLUSIONS— Evidence from
both animal and human studies supports
the premise that high cortisol levels have
an adverse effect on cognitive decline, but
only a few small studies have suggested
that this may occur in people with diabe-
tes (1,18). In this large study of elderly
men and women with type 2 diabetes, we
found that higher fasting morning cortisol
levels were not related to current cogni-
tive ability but were associated with esti-
mated cognitive change, that is, with
some tests of current cognitive function-
ing after adjustment for estimated prior
cognitive ability. Specifically, higher cor-
tisol levels were associated with signifi-
cantly lower general cognitive ability (g)
and with significantly poorer scores on
LNS (working memory) and DST (pro-
cessing speed) and with trends for poorer
cognitive function in other domains, in-
cluding mental flexibility, nonverbal
memory, immediate and delayed mem-
ory, and general cognitive ability.
We found significant associations of
higher cortisol levels with two cognitive
domains, including working memory and
poorer processing speed. The latter is the
first cognitive domain to show a decline
with ageing, shows large declines, and is
an early predictor of dementia (20). The
smaller published studies in the literature
have reported only an association be-
tween cortisol and verbal declarative
memory in younger subjects with diabe-
tes (aged60 years) (1,18). Our subjects
were older, which may explain the differ-
ent findings. In addition, as our subjects
were extensively phenotyped, it was pos-
sible to adjust for several potential con-
founding factors influencing cognitive
performance. Indeed, the relationships
between cortisol and estimated cognitive
change were independent of current met-
Table 2—Correlations between clinical variables, plasma cortisol, and cognition
Cortisol MR LNS VFT DST lnTMT FACES LM g
Demographic variables
Age 0.066* 0.171† 0.151† 0.074* 0.202† 0.185† 0.136† 0.100‡ 0.225†
Female sex 0.003 0.137† 0.035 0.009 0.181† 0.053 0.191† 0.111‡ 0.059
Current smoking 0.021 0.023 0.081* 0.054 0.035 0.015 0.034 0.026 0.014
Alcohol intake (drinks/week) 0.037 0.172† 0.145† 0.145† 0.038 0.028 0.029 0.052 0.134†
Anxiety and depressive symptoms
HADS anxiety 0.010 0.146† 0.137† 0.131† 0.083* 0.121† 0.018 0.056 0.147†
HADS depression 0.044 0.154† 0.131† 0.119† 0.187† 0.179† 0.066* 0.107‡ 0.208†
Diabetes and metabolic variables
Duration of diabetes (years) 0.036 0.008 0.071* 0.069* 0.140† 0.112‡ 0.109‡ 0.033 0.111‡
Systolic blood pressure (mmHg) 0.047 0.019 0.041 0.040 0.011 0.049 0.026 0.009 0.039
Diastolic blood pressure (mmHg) 0.005 0.073* 0.037 0.016 0.027 0.001 0.032 0.043 0.032
Total cholesterol (mmol/l) 0.152† 0.018 0.047 0.022 0.056 0.019 0.048 0.012 0.051
A1C (%) 0.034 0.005 0.033 0.066* 0.038 0.005 0.021 0.012 0.029
BMI 0.088‡ 0.053 0.007 0.054 0.028 0.001 0.016 0.029 0.034
Myocardial infarction 0.009 0.060 0.039 0.026 0.146† 0.086* 0.111‡ 0.030 0.118†
Angina 0.027 0.096‡ 0.066* 0.014 0.157† 0.099‡ 0.081* 0.060 0.141†
ABI 0.048 0.064 0.021 0.010 0.075* 0.026 0.0 0.022 0.049
Cerebrovascular disease 0.011 0.060 0.082* 0.062 0.135† 0.110* 0.066* 0.067* 0.142†
*P  0.05; †P  0.001; ‡P  0.01.
Table 3—Multivariate associations between cortisol and late-life cognition and estimated cognitive change*
Unadjusted
Model 1 Model 2 Model 3 Model 4
Sex and age MHVS
Other
covariates† Interactions‡
§ P  P  P  P  P
MR 0.04 0.28 0.03 0.46 0.04 0.18 0.05 0.08 NSI
LNS 0.06 0.07 0.05 0.13 0.07 0.04 0.07 0.02 0.44 0.002
VFT 0.04 0.27 0.04 0.21 0.03 0.36 0.02 0.51 NSI
DST 0.06 0.07 0.05 0.13 0.07 0.03 0.06 0.04 NSI
lnTMT 0.05 0.13 0.04 0.24 0.05 0.09 0.05 0.12 NSI
FACES 0.05 0.13 0.05 0.08 0.06 0.09 0.06 0.07 NSI
LM 0.04 0.20 0.05 0.16 0.04 0.27 0.05 0.13 NSI
g 0.05 0.20 0.03 0.37 0.05 0.09 0.05 0.06 0.30 0.015
*Cognitive test scores adjusted for MHVS. †Other covariatesHADS score, duration of diabetes, A1C, total cholesterol, BMI, hypertension, smoking, alcohol intake,
myocardial infarction, angina, stroke, ABI, and level of education. ‡Interactions between plasma cortisol and covariates were tested for all models. Significant
interactions were included in the LNS model (cortisol by ABI:   0.572, P 0.002; cortisol by alcohol intake:  0.436, P 0.001) and the g model (cortisol
by ABI:   0.331, P  0.038). §Standardized . NSI, no significant interactions.
Reynolds and Associates
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abolic and cardiovascular status, suggest-
ing that there may be a direct link
between cortisol and the brain. Mechanis-
tically, the hippocampus is highly vulner-
able to both age-related and metabolic
insults and is particularly susceptible to
the damaging effects of elevated cortisol.
Glucocorticoids exert direct effects on
hippocampal neurons, inhibiting long-
term synaptic potentiation (the process
thought to play a role in memory and
learning) and also causing neuronal dam-
age and reducing de novo neurogenesis
(21). Glucocorticoids also have indirect
effects, sensitizing neurons to metabolic
and neurochemical challenges such as
glutamate excess, oxidative stress, and
disrupted calcium homeostasis. How-
ever, the direction of causality remains
unknown as prospective studies of cogni-
tive function in subjects without diabetes
have suggested that hippocampal dys-
function potentially causes elevated corti-
sol levels (22).
The blood samples in our study were
collected under carefully timed condi-
tions in the morning, with all of the sub-
jects in the fasting state. These fasting
cortisol levels in our subjects were high
(mean 730 nmol/l), but high fasting cor-
tisol levels, associated with cognitive de-
cline, were also reported in the much
smaller published studies (1,18). The
mechanisms underlying the high cortisol
levels in diabetes are not known. Cortico-
steroid-binding globulin levels are not el-
evated in diabetes. Thus, these cortisol
concentrations might reflect a stress re-
sponse due to the combination of fasting,
venesection, and the novel clinic setting
in which the samples were obtained.
However, we did not formally assess for
current stress levels. It may be that people
with diabetes are more susceptible to the
effects of stress on plasma cortisol such
that repeated cortisol elevations damage
the hippocampus. Our own studies of im-
paired habituation of cortisol responses to
venepuncture (15) would be consistent
with activation of the HPA axis from higher
centers in type 2 diabetes. Whether subjects
with type 2 diabetes have impaired central
negative feedback sensitivity of the HPA
axis that contributes to high cortisol levels is
not clear, with reports of both impaired
(13,14) and enhanced (23) feedback re-
sponses. Further detailed studies including
examining both the glucocorticoid and
mineralocorticoid receptor components of
central negative feedback sensitivity, as has
recently been described in obesity (24), are
required.
The strengths of this study include the
large sample size and the application of a
battery of seven psychometric tests, which
provides a relatively comprehensive and
validated assessment of cognitive domains
and mood states. There was also detailed
phenotyping for potential confounding or
mediating factors. The study population
had a verified clinical diagnosis of type 2
diabetes and was representative of the wider
type 2 diabetic population (elderly, com-
munity-dwelling men and women with the
full spectrum of severity of type 2 diabetes,
from diet controlled to insulin treated).
Many large-scale studies on people with di-
abetes are restricted to those attending hos-
Figure 1—Association between general cognitive ability factor (g) and fasting cortisol levels in quartiles. Significant decline in general cognitive
ability, g, in association with higher fasting cortisol levels, particularly among those with subclinical atherosclerosis, as indicated by a lower ABI
score (0.8) (P  0.05 in multiple regression analysis model 4 after adjustment for sex, age, MHVS, other covariates, and interactions).
Cortisol and cognition in type 2 diabetes
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pital clinics and biased toward the more
severe end of the spectrum of diabetes. The
main limitation of our study is its cross-
sectional design. We accounted partly for
this by adjusting for a vocabulary measure
(MHVS), which allowed us to estimate life-
time cognitive change. In addition, the use
of multiple statistical tests raises the possi-
bility of our significant findings being type 1
errors. The tests we used are recognized to
be sensitive and so we think this unlikely,
but clearly the results need replicating in
other populations.
If further investigation demonstrates
that the relationship between cortisol and
lifetime cognitive change is causal, such that
higher lifetime levels of cortisol accelerate
age-related cognitive impairment, it is pos-
sible that therapeutic manipulations that
lower cortisol levels may help to improve
cognitive function. Access of cortisol to the
glucocorticoid receptor is regulated by local
activity of the 11-hydroxysteroid dehy-
drogenase enzymes (11-HSDs), which
catalyze the interconversion of the active
steroid cortisol and its inactive metabolite
cortisone. 11-HSD1 reactivates cortisol
from inactive cortisone in many central ner-
vous system and metabolic sites, increasing
activation of the glucocorticoid receptor.
In a small, randomized, double-blind,
placebo-controlled, crossover study, ad-
ministration of the 11-HSD inhibitor, car-
benoxolone, improved verbal fluency
after 4 weeks in 10 healthy elderly men
(aged 55–75 years) and improved verbal
memory after 6 weeks in 12 people with
type 2 diabetes (25). Whether this short-
term effect on cognitive ability could be
reproduced over longer time periods, and
therefore help reduce the cognitive de-
cline associated with aging, is unknown.
Notably, verbal fluency was not related to
fasting plasma cortisol in the current
study.
In conclusion, morning cortisol levels
in elderly people with type 2 diabetes are
high, with deleterious effects on cognitive
function. Further investigation is re-
quired to determine the direction and na-
ture of this relationship, which, if causal,
would support the use of therapeutic
strategies to lower cortisol action (25) to
ameliorate cognitive decline in individu-
als with type 2 diabetes.
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